Chemocentryx reported $-38608000 in Net Income for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Net Income Change
Abbvie ABBV:US $ 4490M 446M
Alnylam Pharmaceuticals ALNY:US $ -240.34M 18.12M
Amgen AMGN:US $ 1476M 423M
AstraZeneca AZN:LN 386M 733M
Bayer BAYN:GR € 3291M 2130M
Biogen BIIB:US $ 303.8M 64.4M
Biomarin Pharmaceutical BMRN:US $ 120.8M 178.7M
Bristol Myers Squibb BMY:US $ 1278M 1094M
Chemocentryx CCXI:US $ -38.61M 1.92M
Glaxosmithkline GSK:US $ 1802M 1053M
GlaxoSmithKline GSK:LN 1802M 1053M
Johnson & Johnson JNJ:US $ 5149M 413M
Macrogenics MGNX:US $ -66.44M 8.42M
Merk MRK:US $ 4310M 552M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Novartis NOVN:VX SF 2222M 14086M
Pfizer PFE:US $ 7863M 4470M
Sarepta Therapeutics SRPT:US $ -105.02M 16.96M
Takeda 4502:JP Y -11358M 69127M
Teva Pharmaceutical TEVA:IT -955000000 797M
YTE INCY:US $ 37.99M 525.86M